James Barry Sells 700 Shares of Bio-Rad Laboratories (NYSE:BIO) Stock

Bio-Rad Laboratories, Inc. (NYSE:BIO) EVP James Barry sold 700 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $306.18, for a total transaction of $214,326.00. Following the completion of the transaction, the executive vice president directly owned 510 shares in the company, valued at approximately $156,151.80. The trade was a 57.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Bio-Rad Laboratories Stock Up 2.1%

Shares of NYSE BIO opened at $313.82 on Wednesday. Bio-Rad Laboratories, Inc. has a 12 month low of $211.43 and a 12 month high of $373.69. The firm has a market capitalization of $8.49 billion, a price-to-earnings ratio of -12.91 and a beta of 1.04. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. The business has a 50-day moving average of $300.66 and a 200-day moving average of $268.65.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Wednesday, October 29th. The medical research company reported $2.26 EPS for the quarter, missing analysts’ consensus estimates of $2.30 by ($0.04). The company had revenue of $653.00 million during the quarter, compared to the consensus estimate of $651.30 million. Bio-Rad Laboratories had a positive return on equity of 4.18% and a negative net margin of 26.43%.Bio-Rad Laboratories’s quarterly revenue was up .5% on a year-over-year basis. During the same period in the previous year, the company earned $2.01 EPS. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. Sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BIO has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, November 1st. Royal Bank Of Canada upped their price objective on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an “outperform” rating in a report on Friday, August 1st. Zacks Research upgraded shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 26th. Wells Fargo & Company raised their price objective on Bio-Rad Laboratories from $265.00 to $340.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Finally, Weiss Ratings upgraded shares of Bio-Rad Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, October 30th. Three investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Bio-Rad Laboratories has a consensus rating of “Moderate Buy” and an average price target of $358.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Principal Financial Group Inc. increased its holdings in shares of Bio-Rad Laboratories by 0.5% during the 1st quarter. Principal Financial Group Inc. now owns 44,343 shares of the medical research company’s stock valued at $10,800,000 after purchasing an additional 236 shares in the last quarter. Crossmark Global Holdings Inc. boosted its holdings in shares of Bio-Rad Laboratories by 14.6% during the 1st quarter. Crossmark Global Holdings Inc. now owns 966 shares of the medical research company’s stock worth $235,000 after purchasing an additional 123 shares during the last quarter. Amundi grew its stake in shares of Bio-Rad Laboratories by 16.4% in the 1st quarter. Amundi now owns 23,336 shares of the medical research company’s stock valued at $5,478,000 after buying an additional 3,294 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in Bio-Rad Laboratories during the first quarter worth $816,000. Finally, Acadian Asset Management LLC lifted its holdings in shares of Bio-Rad Laboratories by 79.6% in the 1st quarter. Acadian Asset Management LLC now owns 73,431 shares of the medical research company’s stock worth $17,878,000 after acquiring an additional 32,534 shares during the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.